Is tesamorelin available in Australia?

Egrifta is not TGA-approved in Australia, but tesamorelin is available through compounding pharmacies and research suppliers. Check current regulations.

Do I need to cycle tesamorelin?

Clinical trials used continuous daily dosing for 26–52 weeks without cycling. Unlike hexarelin, there is no significant desensitisation with tesamorelin. That said, fat regain occurs when treatment is discontinued.

Growth Hormone

Tesamorelin

Tesamorelin Acetate

FDA-approved GHRH analog that reduces visceral fat

Tesamorelin is an FDA-approved GHRH analog specifically indicated for reducing visceral adipose tissue. One of the few peptides with current regulatory approval.

Admin routes

Subcutaneous

Popularity

Medium

Side effects

Generally mild

Vendors

1 rated

Key benefits

1FDA-approved for visceral fat reduction

2More potent than sermorelin with longer duration

3Preserves natural GH pulsatility

4Reduces trunk/visceral fat specifically

5Improved IGF-1 levels

6Well-characterised safety profile from Phase 3 trials

What to expect

Week 1–4

GH and IGF-1 levels begin rising

Week 4–8

Subtle visceral fat reduction measurable on scans

Week 8–16

Significant trunk fat reduction in clinical data

Week 16–26

Maximum visceral fat reduction achieved in trials

Based on community reports and published research. Individual results vary significantly.

🏪Rated vendors

View all →

No vendors listed for United States yet.

View all vendors →

Vendor ratings are based on community feedback and are not endorsements. Always verify third-party certificates of analysis (CoA) and check your local regulations before purchasing.

Dosing protocols

Visceral fat reduction

Dose

2 mg

Frequency

Once daily

Duration

3–6 months minimum

GH optimisation

Dose

1–2 mg

Frequency

Once daily before bed

Duration

3–6 months

Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.

Research status|FDA-approved (Egrifta, 2010) - extensive Phase 3 data

Overview

Tesamorelin is a synthetic GHRH analog approved by the FDA in 2010 (brand name Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It stimulates GH release from the pituitary similarly to sermorelin but with greater potency and a longer half-life due to the addition of a trans-3-hexenoic acid group. Off-label, it is widely used in longevity medicine for visceral fat reduction and GH optimisation.

How it works

Binds to GHRH receptors on the anterior pituitary, stimulating natural GH release. The trans-3-hexenoic acid modification increases resistance to enzymatic degradation (DPP-IV), extending its duration of action. Like sermorelin, it preserves the body's natural GH feedback mechanisms. Clinical trials showed significant reductions in trunk fat (visceral adipose tissue) without affecting subcutaneous fat or glucose tolerance.

Side effects

Injection site reactions (erythema, pruritus)

mildCommon

Joint pain/arthralgia

mildUncommon

Peripheral oedema

mildUncommon

Paraesthesia (tingling in extremities)

mildUncommon

Research history

2004

Phase 2 trials by Theratechnologies demonstrate visceral fat reduction

2007

Phase 3 JAMA publication confirms efficacy

2010

FDA approves Egrifta for HIV-associated lipodystrophy

2014

Further studies show liver fat reduction benefits

2020s

Off-label adoption in longevity and anti-aging clinics

Tesamorelin vs sermorelin

Both are GHRH analogs that stimulate natural GH production. Tesamorelin is more potent, has FDA approval (stronger safety data), and has been specifically proven to reduce visceral fat in clinical trials. Sermorelin is less potent but cheaper and more widely available through compounders. For visceral fat reduction specifically, tesamorelin has the stronger evidence base.

Recommended products

Hand-picked for this compound. Ships via Amazon 🇺🇸

❄️

Storage & Transport

Portable Insulin Cooler Fridge

Portable peptide fridge with precise 2-8C cooling. Battery powered, travel-ready. Designed for insulin/peptide storage.

📖

References

[1]Falutz J, et al. 'Effects of tesamorelin on body composition and metabolic parameters.' JAMA, 2007.
[2]Stanley TL, et al. 'Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients.' JAMA, 2014.

Frequently asked questions

Related peptides

Sermorelin

Growth Hormone

The original GH-releasing peptide - FDA-approved since 1997

0 rated vendors

CJC-1295 + Ipamorelin

Growth Hormone

The growth hormone secretagogue stack that works while you sleep

5 rated vendors

AOD-9604

Weight Management

The HGH fragment that targets fat without the side effects

3 rated vendors

Community experiences

Share your experience with Tesamorelin. Effects, side effects, protocol details - help others make informed decisions.

No community reviews yet. Be the first to share your experience with Tesamorelin.

Need to calculate your dose?

Use our free reconstitution calculator to work out syringe units for Tesamorelin.

Open Calculator

Found this useful?

Share this guide

Get the free Beginner Peptide Protocol

Which peptides to start with, what to avoid, and safe handling. Delivered to your inbox.

Vendors

Rated suppliers

Quality, shipping, and service scores

Store

Supplies

Syringes, bac water, storage

Guides

How-to guides

Storage, reconstitution, and travel

Disclaimer: This guide is for educational and informational purposes only. It is not medical advice. The dosing protocols listed are sourced from published research and community reports and do not constitute a recommendation. Always consult a qualified healthcare professional before using any peptide. Check your local regulations regarding peptide purchase and use.